About BOL Pharma
A leader in cannabis Innovation
ABOUT /
ABOUT BOL PHARMA
Established in 2007 under the name “Shaifa LaHaim” (Breath of Life) , BOL is amongst Israel’s largest and leading medical cannabis companies, accredited throughout all value chains including cultivation, extraction, import, export and R&D, marketing and distributing only to name a few.
BOL Pharma is committed to the most stringent standards of the Israeli Ministry of Health IMC-GMP, and the only company manufacturing THC API under EU-GMP accreditation.
BOL became the first company in Israel to receive a permit to export and import cannabis in 2020.
ABOUT /
OUR VISION
BOL is set to lead the Israeli cannabis industry in innovation, R&D and product versatility of brands and strains.
The company leads the market through a wide variety of the highest quality of strains and cannabis related products, and is committed to serving patients with consistent and premium quality products, with continuous and ongoing development, research and innovation of healthcare and wellness products through strong positioning and advanced technologies, while continuously expanding its strategic alliances, both domestic and international.
ABOUT /
LEADERSHIP TEAM
A highly experienced leadership team with a proven track record.
CEO
20+ years of senior leadership experience in FMCG & OTC companies such as P&G and RB. Vast Local and Global experience.
Expert in Consumer Understanding, Branding, Innovation, Commercialization of technologies.
COO
10+ years of leadership experience in operations, logistics, supply chain and IS Former COO of Reckitt Benckiser and Renuar.
VP R&D
10 years of product development in pharma and cannabis companies. Advisory board member of Cannegev Incubator.
VP HR
20+ years experience as HR specialist, establishing and leading HR in various global and local organizations.MBA in Organization Consulting.
Head of BizDev
30+ years of diversified business experience within international and emerging markets, paving BOL forward to powerful global positioning and strong strategic alliances.
ABOUT /
facilities and technology
BOL Pharma is an INNOVATION LEADER with
- Proprietary Extraction Capabilities
- Drug Delivery Technologies
- Advanced Formulations
- Enhanced Bioavailability Methodologies
We have fully integrated operations including
- Cultivation and farming own strains
- State of the art Labs
- Advanced R&D
- Own plant –proprietary extraction methods, various product forms
- Distribution Center
All operating under the highest regulatory standards
The Agriculture Division
The agriculture division at BOL includes 6 departments that compliment all links of the value chain: growth, cultivation of strains, research and development, independent nursery and post-harvest.
• Cultivation – A department that operates within the company’s spacious complex.
• Laboratory – For tissue cultures for plant health and molecular biology in plants.
• R&D – Works with best researches in the cannabis industry.
• Planting – Produces seedlings that originate from tissue culture and provides seedlings to foreign customers.
• Growing – Responsible for growing greenhouses.
• Post-harvest – A department that conducts a process combining wet trimming mechanization, dry trimming mechanization, a manual trimming center and cooling processes based on analyses, active ingredients and terpenes.
The synergies arising from the departments of our agricultural division, in combination with other divisions like the packaging division, the analytical laboratory and the medical support units, allow the agricultural division to grow climate-adapted cannabis flowers in controlled growing conditions for products that meet the needs of patients and consumers.
The Lab
The laboratory includes analytics, microbiology and R&D teams with a wealth of experience in quality control from the world of pharma under GMP conditions.
Advanced analytical equipment:
• HPLCs with UV/PDA Detectors
• HPLCs with Fluorescence Detectors
• GCs with FID
• FTIR
• KF and Mister Analyzer
Methods:
• Methods for quantifying the content of 15 cannabinoids (quantification threshold 0.1%): THC, THCA, CBD, CBDA, CBN, CBG, CBGA, CBC, CBCA, CBDV, CBDVA, CBL, CBLA, THCV, Δ8-THC.
• Methods for quantifying toxins (quantification threshold: 1.0µg/Kg): Ochratoxin A, Aflatoxin B1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2.
• Methods for microbial tests: Total Combined Yeasts/Molds Count (TYMC), Total Aerobic Microbial Count (TAMC), Specified Pathogens: S.Aureus, Salmonella, Listeria, P. Aeruginosa, Enterobacteria, E. Coli, E. Coli 0157, Shigella
• A method for quantifying organic solvent residues in THC, API’S and CBD.
• Methods for identification, quantification of contents and non-cleaning in the THC API, according to the German monograph DAC.
• Methods for testing water content using KF and moister analyzer.
• A method for quantifying terpenes.
All methods have been fully validated for all relevant products.
Activity:
• Performing routine release tests for factory products.
• Performing stability tests.
• Performing unique tests for the R&D department.
• Improving existing methods and developing new methods.
• Providing inductive outdoor services at the various stages of cannabis cultivation.
THC Production
We are proud of our unique ability to produce cannabinoid extracts and API (Dronabinol) for export purposes. Over the years, we have become the trusted API’s suppliers for leading pharmaceutical companies, as well as universities and research partners in Israel and around the world due to the company’s ability to meet DAC and USP pharmaceutical standards.
OUR PARTNERS /
STRONG GLOBAL PARTNERSHIPS
CONTACT US /
How can we help?